Deborah Schmiel

FDA investigator

Appears on 5 documents from 2016 to 2024, most often at sites in South Korea. Most often cites control of microbiological contamination (21 CFR 211.113).

5
Documents on file
5.4
Observations per 483
2016
First seen
2024
Most recent

What they cite most

From 26 observations

Activity by year

2016: 1, 2018: 2, 2019: 1, 2024: 1

Where

South Korea 2 · Austria 1 · Denmark 1 · Italy 1

Is Deborah Schmiel coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

5 documents, newest first
FirmOpen
483 BSP Pharmaceuticals SpAFeb 29, 2024 · Latina Scalo, Italy
483 FUJIFILM Diosynth Biotechnologies Denmark ApSOct 11, 2019 · Hillerod, Denmark
483 Samsung Biologics Co., Ltd.Jun 26, 2018 · Incheon, South Korea
483 Sandoz GmbHFeb 20, 2018 · Langkampfen, Austria
483 Samsung Biologics Co., Ltd.Jun 22, 2016 · Incheon, South Korea

About this profile

What does Deborah Schmiel inspect?

Deborah Schmiel appears on 5 documents on file covering 4 sites, most often in South Korea.

What do they cite most often?

21 CFR 211.113 (control of microbiological contamination), followed by 21 CFR 211.192 and 21 CFR 211.68.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Deborah Schmiel is dated Feb 29, 2024.

FDA Investigator Deborah Schmiel: 483s & Inspections · FDA Intel